• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Neoplasia (New York N.Y.) >LY293111 Improves Efficacy of Gemcitabine Therapy on Pancreatic Cancer in a Fluorescent Orthotopic Model in Athymic Mice
【2h】

LY293111 Improves Efficacy of Gemcitabine Therapy on Pancreatic Cancer in a Fluorescent Orthotopic Model in Athymic Mice

机译：LY293111在无荧光小鼠原位荧光模型中提高吉西他滨治疗对胰腺癌的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pancreatic cancer has an abysmal prognosis because of late diagnosis and lack of effective therapeutics. New drugs are desperately needed. The present study determined the effect of the LTB4 receptor antagonist, , on tumor growth and metastases in a fluorescent orthotopic model of pancreatic cancer. Pancreatic cancer cells (S2-013) with stable expression of enhanced green fluorescent protein were implanted into the duodenal pancreatic lobe of athymic mice. Animals were allocated to four groups (eight mice per group): control (no treatment); ; gemcitabine; and + gemcitabine. Monitoring of the surgical procedure and follow-up examinations at 2, 3, and 4 weeks after implantation to monitor tumor growth and metastases were performed using a fluorescence microscope and the reversible skin-flap technique. A staging and scoring system was developed to evaluate tumor progression, based on the TNM classification. Control animals developed end-stage disease with invasive cancer, metastases, and cachexia. Tumor growth and incidence of metastases were significantly reduced in all treated mice. However, combined treatment with and gemcitabine was most effective. is a novel therapeutic agent for pancreatic cancer, which improves the efficacy of gemcitabine. It is well tolerated and can be administered orally and, therefore, provides a new hope for patients suffering from pancreatic adenocarcinoma.
机译：由于晚期诊断和缺乏有效的治疗方法，胰腺癌的预后很差。迫切需要新药。本研究确定了LTB4受体拮抗剂对胰腺癌荧光原位模型中肿瘤生长和转移的影响。将稳定表达增强的绿色荧光蛋白的胰腺癌细胞（S2-013）植入无胸腺小鼠的十二指肠胰叶中。将动物分为四组（每组八只小鼠）：对照组（不治疗）； ;吉西他滨和吉西他滨。使用荧光显微镜和可逆皮瓣技术对植入后第2、3和4周的手术过程进行监测并进行随访检查，以监测肿瘤的生长和转移。基于TNM分类，开发了一种分期和评分系统以评估肿瘤进展。对照动物发展为晚期疾病，具有浸润性癌，转移和恶病质。在所有治疗的小鼠中，肿瘤的生长和转移的发生率均显着降低。但是，与吉西他滨联合治疗最有效。是用于胰腺癌的新型治疗剂，可提高吉西他滨的疗效。它具有良好的耐受性，可以口服，因此为胰腺腺癌患者提供了新的希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号